Quarterly ResultMay 14, 2026, 07:22 AM
Invivyd Q1 Net Loss $41.4M; Raises Going Concern Doubt
AI Summary
Invivyd, Inc. reported a net loss of $41.4 million for the three months ended March 31, 2026, a significant increase from $16.3 million in the prior year. The company disclosed substantial doubt about its ability to continue as a going concern, indicating insufficient cash to fund operations beyond one year without additional financing. Despite this, product revenue grew 21.6% to $13.7 million, and the company continues to advance its clinical programs for VYD2311, VBY329, and VMS063, with VYD2311 receiving FDA Fast Track designation.
Key Highlights
- Invivyd raised substantial doubt about its ability to continue as a going concern.
- Net loss increased to $41.4 million in Q1 2026 from $16.3 million in Q1 2025.
- Product revenue grew 21.6% to $13.7 million in Q1 2026 from $11.3 million in Q1 2025.
- Cash and cash equivalents decreased to $184.2 million as of March 31, 2026.
- Research and development expenses surged 188.8% to $30.7 million in Q1 2026.
- Selling, general and administrative expenses rose 49.9% to $25.1 million in Q1 2026.
- Net loss per share was $(0.13) in Q1 2026, compared to $(0.14) in Q1 2025.
- FDA granted Fast Track designation for VYD2311 for COVID-19 prevention.